Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Jun 20 2017

Full Issue

Bristol-Myers' Supreme Court Victory Could Have Far-Reaching Ramifications In Liability Cases

The case centered around whether plaintiffs residing outside of the state who claim they were harmed by the company's blood thinner could join in a lawsuit brought by California residents. "It will extremely limit the notion that large companies can be sued by anyone, anywhere," said one lawyer.

The Associated Press: High Court Sides With Drugmaker In Plavix Lawsuit

The Supreme Court says hundreds of out-state-residents can’t sue drugmaker Bristol-Myers Squibb Co. in California state court over adverse reactions to the blood thinner Plavix. The justices ruled 8-1 Monday that there was not a strong enough connection between the claims against the drugmaker and the company’s ties to the state. The ruling is a win for Bristol-Myers Squibb and other companies that want to avoid lawsuits in state courts seen as more favorable to plaintiffs. (6/19)

Politico: Supreme Court Ruling In Drug Case Could Have Big Implications For Product Liability

A Supreme Court decision Monday could make it harder for large groups of plaintiffs to sue corporations in state courts for damages caused by manufacturers' products. Bristol-Myers Squibb prevailed in its effort to get the Supreme Court to limit where patients can seek compensation for harm caused by drugs. But the ruling will echo beyond the pharmaceutical industry to potentially affect any liability case in which consumers allege harm caused by a deficient product, including automobiles, tobacco, food and other mass litigation like consumer claims of financial fraud by a company. It could also affect lawsuits against companies being accused of environmental wrongdoing. (Karlin-Smith, 6/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF